Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was ...
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & ...
Investor's Business Daily on MSN6d
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBioAlnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shot up 8.9% during trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $44.00 to $50.00. JPMorgan ...
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...
Pharmaceutical Technology on MSN6d
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drugAmvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic ...
BridgeBio Pharma said Finance Chief Brian Stephenson is leaving the company for personal reasons and will be replaced by Thomas Trimarch, who will continue holding the president role.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback